Sigilon Therapeutics Profit Margin

Sigilon Therapeutics (SGTX) currently reports a profit margin of -167.52% as of June 2023. That compares with -665.17% in the prior-year period — up 74.8% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Sigilon Therapeutics's profit margin history and peer comparisons.

Sigilon Therapeutics's profit margin increased from -665.17% to -167.52% — a 74.8% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sigilon Therapeutics's profit margin of -167.52% is lower than the Healthcare sector average of 13.89%. That is roughly 1306.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sigilon Therapeutics's current -167.52% should be judged against Healthcare norms (sector average: 13.89%) and against SGTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -167.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Sigilon Therapeutics, and consider following SGTX for alerts when major investors trade the stock.